On September 15th, Crest and Oral-B announced the kick off of National Gingivitis Awareness Month, with a press conference in Greeley Square Park, Manhattan, featuring “White Collar” star, Tiffani Thiessen. Thiessen is helping Crest and Oral-B to bring attention to the early gum disease, gingivitis, which affects more than fifty percent of American adults¹. Along with the declaration, Crest and Oral-B are helping consumers prevent and reverse gingivitis by introducing a new member to the Crest® Pro-Health® family, Crest® Pro-Health® Clinical Gum Protection. The new, advanced formula of Clinical Gum Protection provides Crest’s highest level of protection against the plaque bacteria that can cause gingivitis and with regular use, is clinically proven to help reverse gingivitis in just four weeks.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/crestprohealth/44592/
Rules-Based Medicine, Inc. (RBM), today announced the widespread commercial availability of VeriPsych™, the first and only blood-based diagnostic test to aid in confirming the diagnosis of recent onset schizophrenia, a potentially devastating and costly mental illness that affects about 24 million people worldwide. VeriPsych is an innovative molecular diagnostic tool designed to complement the healthcare provider’s clinical impression.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rulesbasedmedicine/46237/
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
More than eight in 10 Americans ages 50-64 believe healthy teeth and gums are essential to maintaining overall good health, yet only a third say they are taking good care of their oral health, according to a survey conducted by the American Dental Association (ADA), with Crest® and Oral-B®. To help bridge this gap, Crest Pro-Health and actress, author, and health advocate Marilu Henner are committed to educating older adults about the importance of gum health during the 2nd annual National Gingivitis Awareness Month this September.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/crestprohealth/49093/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
As soon as you start feeling run down or have other flu-like symptoms, take Oscillococcinum.
Oscillo® is supported by published clinical studies, as well as more than 65 years of use throughout the world.
-Clinical studies show that Oscillo reduces the severity and duration of flu-like symptoms such as headache, body aches, chills and fever
-Great taste and convenient to take
-No side effects; no drug interactions; non-drowsy
-Safe for everyone 2 years of age and older
To view Multimedia News Release, go to http://www.multivu.com/players/English/45775-Boiron-Oscillococcinum/
